MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
Enlivex Therapeutics Ltd. Operating Expenses 2011-2026 | ENLV
Annual Operating Expenses Enlivex Therapeutics Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 19.3 M | - | 8.62 M | 5.3 M | 5.96 M | 15.9 M | 15.5 M | 7.08 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.3 M | 5.3 M | 11.1 M |
Quarterly Operating Expenses Enlivex Therapeutics Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 3.81 M | - | - | - | 2.23 M | - | - | - | 1.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.81 M | 1.3 M | 2.45 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Rigel Pharmaceuticals
RIGL
|
127 M | $ 33.23 | -4.03 % | $ 584 M |  USA |
 |
Graybug Vision
GRAY
|
23.1 M | - | -11.23 % | $ 9.65 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 20.15 | -2.68 % | $ 2.54 B | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 64.66 | -1.37 % | $ 12.4 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Certara
CERT
|
237 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
425 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
31.5 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
23.4 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
12.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
12 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Denali Therapeutics
DNLI
|
502 M | $ 20.02 | -4.67 % | $ 3.29 B | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 17.54 | -3.36 % | $ 450 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
52.3 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
104 M | - | 7.55 % | $ 38.1 M | USA |